ArticleFrontiers in oncology2026
Real-world treatment patterns and outcomes for patients with extensive-stage small-cell lung cancer treated in US community oncology practices.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive malignancy with a poor prognosis. Advances have been made in the treatment landscape in the past decade, including integrating immune checkpoint inhibitors (ICIs) with platinum-based chemotherapy in the first-line (1L) setting and the recent approval of T-cell engagers in subsequent lines. Despite these developments, efficacy remains limited, and therapeutic resistance emerges rapidly. This study aimed to evaluate treatment patterns and clinical outcomes among real-world ES-SCLC patients treated in US community oncology practices. Methods: This retrospective cohort study used secondary structured electronic health records (EHR) data from the iKnowMed system. Adult patients diagnosed with Results: Among 3,484 eligible patients, 86.6% had Conclusions: This study shows high utilization of ICI plus chemotherapy in 1L ES-SCLC, consistent with clinical guidelines. Despite this uptake, poor survival outcomes persisted, highlighting substantial unmet needs and the importance of developing novel treatment strategies and continuing to evaluate emerging therapies in real-world settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.